Fig. 6

Correlations of YBX1 expression with drug response, immune cells infiltration and clinic outcome. A Violin plot of YBX1 expression in MM patients with different drug response pre and 2 cycles post treatment. B Box plot showing YBX1 expression in responders and non-responders at different timepoints from GSE161195 dataset. C KM plots and analysis for OS (left, logrank test, two-sided p = 0.00012, HR = 1.742) and PFS (right, logrank test, two-sided p = 0.000167, HR = 1.407) comparing NDMM patients in CoMMpass dataset with low YBX1 (blue) and high YBX1 expression (red). D GSEA analysis showing significant positive enrichment (top) and negative enrichment (bottom) of biological processes and signaling pathways in tumor cells from the YBX1-high group. E The differential score of 28 immune cell type signatures by ssGSEA method in patients from CoMMpass database with low and high YBX1 expression. F qPCR (up) and western blot (bottom) analysis showing the mRNA and protein levels of YBX1 in HMCLs respectively after transduction of sh-YBX1 or sh-NC. G Proliferation curves of U266 (left) and OPM2 (right) cell lines with transduction of sh-YBX1 or sh-NC using CCK-8 assay. H Viability of CD138-positive primary myeloma cells 96 h after transfection with YBX1 shRNA. I qPCR analysis showing the mRNA expression of key targets in U266 (left) and OPM2 (right) cell lines after transduction of sh-YBX1 or sh-NC. Error bars in F–I denoted mean ± SD. Statistical analyses in A, B, E were performed by Wilcoxon test and by two-tailed Student t test in F–I. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001